211 related articles for article (PubMed ID: 6488689)
1. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
[TBL] [Abstract][Full Text] [Related]
2. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype.
Spina E; Steiner E; Ericsson O; Sjöqvist F
Clin Pharmacol Ther; 1987 Mar; 41(3):314-9. PubMed ID: 3816019
[TBL] [Abstract][Full Text] [Related]
3. Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations.
von Bahr C; Birgersson C; Morgan ET; Eriksson O; Göransson M; Spina E; Woodhouse K
Xenobiotica; 1986 May; 16(5):391-400. PubMed ID: 3739365
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.
von Bahr C; Spina E; Birgersson C; Ericsson O; Göransson M; Henthorn T; Sjöqvist F
Biochem Pharmacol; 1985 Jul; 34(14):2501-5. PubMed ID: 4015690
[TBL] [Abstract][Full Text] [Related]
5. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.
Mellström B; Bertilsson L; Säwe J; Schulz HU; Sjöqvist F
Clin Pharmacol Ther; 1981 Aug; 30(2):189-93. PubMed ID: 7249504
[TBL] [Abstract][Full Text] [Related]
6. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
7. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
[TBL] [Abstract][Full Text] [Related]
8. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Alván G; Grind M; Graffner C; Sjöqvist F
Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
[TBL] [Abstract][Full Text] [Related]
9. Desmethylimipramine overdose: nonlinear kinetics in a slow hydroxylator.
Spina E; Henthorn TK; Eleborg L; Nordin C; Säwe J
Ther Drug Monit; 1985; 7(2):239-41. PubMed ID: 4024220
[TBL] [Abstract][Full Text] [Related]
10. Correlation between nortriptyline and debrisoquine hydroxylation in the human liver.
von Bahr C; Birgersson C; Blanck A; Göransson M; Mellström B; Nilsell K
Life Sci; 1983 Aug; 33(7):631-6. PubMed ID: 6410141
[TBL] [Abstract][Full Text] [Related]
11. Interethnic dissociation between debrisoquine and desipramine hydroxylation.
Rudorfer MV; Lane EA; Potter WZ
J Clin Psychopharmacol; 1985 Apr; 5(2):89-92. PubMed ID: 3988975
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of cimetidine and ranitidine on imipramine demethylation and desmethylimipramine hydroxylation by human liver microsomes.
Spina E; Koike Y
Eur J Clin Pharmacol; 1986; 30(2):239-42. PubMed ID: 3709653
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of desipramine 2-hydroxylation by quinidine and quinine.
Steiner E; Dumont E; Spina E; Dahlqvist R
Clin Pharmacol Ther; 1988 May; 43(5):577-81. PubMed ID: 3365919
[TBL] [Abstract][Full Text] [Related]
14. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of desipramine 2-hydroxylation by quinidine and quinine in rapid and slow debrisoquine hydroxylators.
Spina E; Steiner E; Dumont E; Dahlqvist R
Psychopharmacol Ser; 1989; 7():201-5. PubMed ID: 2687858
[No Abstract] [Full Text] [Related]
16. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
17. Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects.
Woolhouse NM; Adjepon-Yamoah KK; Mellström B; Hedman A; Bertilsson L; Sjöqvist F
Clin Pharmacol Ther; 1984 Sep; 36(3):374-8. PubMed ID: 6467797
[TBL] [Abstract][Full Text] [Related]
18. Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver.
Birgersson C; Morgan ET; Jörnvall H; von Bahr C
Biochem Pharmacol; 1986 Sep; 35(18):3165-6. PubMed ID: 3753522
[No Abstract] [Full Text] [Related]
19. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
[TBL] [Abstract][Full Text] [Related]
20. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.
Yue QY; Svensson JO; Alm C; Sjöqvist F; Säwe J
Br J Clin Pharmacol; 1989 Dec; 28(6):639-45. PubMed ID: 2611086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
